ArticleClinical rheumatology2026
Targeting RIPK1 is a promising therapeutic avenue for systemic lupus erythematosus.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNecroptosis plays a significant role in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). Nonetheless, the therapeutic potential of necroptosis inhibition in these conditions remains unclear.
methodsThis study examines the systemic therapeutic effects of Necrostatin-1 (Nec-1), an inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1), in MRL/lpr lupus-prone mice.
resultsImmunohistochemical analysis in renal tissue of active LN patients and MRL/lpr mice demonstrated elevated levels of pRIPK1 and pMLKL. A 28-day treatment with Nec-1 significantly ameliorated the histological manifestations of SLE, including alopecia, skin erythema, arthritis, and nephritis, in MRL/lpr mice. Notably, it mitigated acute lesion features such as LN perivascular inflammation and reduced the presence of pRIPK1 and pMLKL positive immune cells in the kidney. Mechanistically, Nec-1 treatment may exert its therapeutic effects on SLE by decreasing the proportion of Th17 cells in MRL/lpr mice.
conclusionThese findings suggest that targeting RIPK1 hold promise as a therapeutic strategy for the management of SLE. Key Points • Necroptosis markers are upregulated in renal immune cells of active LN patients and MRL/lpr mice. • Necrostatin-1 (Nec-1) ameliorates clinical, serological, and histological features in MRL/lpr mice. • Nec-1 exerts its therapeutic effect by inhibiting necroptosis in immune cells, which subsequently reduces Th17 cell frequency and IL-17A levels.
Indexed as
Identifiers
42319616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.